Xortx TherapeuticsXRTX
13F holders, Q2 2024 (June 30)5holders +1
2new positions
1sold out
1famous investor
$1.92avg. 13F price*
At the end of Q2 2024, 5 institutions reported holding Xortx Therapeutics Inc. (XRTX) in their 13F filings, up 1 from Q1 2024. 2 opened new positions and 1 sold out. The largest holders were Citadel Advisors ($23K), Osaic Holdings, Inc. ($2K) and Royal Bank of Canada ($2K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Xortx Therapeutics Inc.
- CUSIP
- 98420Q306
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $25K |
| Exits | 1 | $60K |
All 13F filers, Q1 2024 → Q2 2024: 13,559 shares bought and 14,994 shares sold, net −1,435 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Citadel Advisors | 0.00% | New | 12,333 | $23K |
| Osaic Holdings, Inc. | 0.00% | No change | 1,153 | $2K |
| Royal Bank of Canada | 0.00% | New | 1,226 | $2K |
| JPMorgan Chase & Co. | 0.00% | No change | 254 | $1K |
| Clearstead Advisors, LLC | 0.00% | No change | 277 | $527 |
"% of holder's portfolio" is XRTX's weight in each manager's 13F, not the share of Xortx Therapeutics Inc. the manager owns.